<VariationArchive VariationID="1048814" VariationName="NM_000251.3(MSH2):c.459del (p.Ala154fs)" VariationType="Deletion" Accession="VCV001048814" Version="2" RecordType="classified" NumberOfSubmissions="4" NumberOfSubmitters="2" DateLastUpdated="2024-06-23" DateCreated="2021-04-13" MostRecentSubmission="2023-12-24">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="1037212" VariationID="1048814">
      <GeneList>
        <Gene Symbol="MSH2" FullName="mutS homolog 2" GeneID="4436" HGNC_ID="HGNC:7325" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>2p21-16.3</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="2" Accession="NC_000002.12" start="47403067" stop="47709830" display_start="47403067" display_stop="47709830" Strand="+" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="2" Accession="NC_000002.11" start="47630205" stop="47710366" display_start="47630205" display_stop="47710366" Strand="+" />
          </Location>
          <OMIM>609309</OMIM>
          <Haploinsufficiency last_evaluated="2021-10-13" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=MSH2">Sufficient evidence for dosage pathogenicity</Haploinsufficiency>
          <Triplosensitivity last_evaluated="2021-10-13" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=MSH2">No evidence available</Triplosensitivity>
          <Property>gene_acmg_incidental_2013</Property>
          <Property>gene_acmg_incidental_2016</Property>
          <Property>gene_acmg_incidental_2021</Property>
          <Property>gene_acmg_incidental_2022</Property>
        </Gene>
      </GeneList>
      <Name>NM_000251.3(MSH2):c.459del (p.Ala154fs)</Name>
      <CanonicalSPDI>NC_000002.12:47410184:CC:C</CanonicalSPDI>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>2p21</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="2" Accession="NC_000002.12" start="47410185" stop="47410185" display_start="47410185" display_stop="47410185" variantLength="1" positionVCF="47410184" referenceAlleleVCF="TC" alternateAlleleVCF="T" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="2" Accession="NC_000002.11" start="47637324" stop="47637324" display_start="47637324" display_stop="47637324" variantLength="1" referenceAllele="TC" alternateAllele="T" positionVCF="47637323" referenceAlleleVCF="TC" alternateAlleleVCF="T" />
      </Location>
      <ProteinChange>A154fs</ProteinChange>
      <ProteinChange>A88fs</ProteinChange>
      <HGVSlist>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000002.11" sequenceAccession="NC_000002" sequenceVersion="11" change="g.47637325del" Assembly="GRCh37">
            <Expression>NC_000002.11:g.47637325del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000002.12" sequenceAccession="NC_000002" sequenceVersion="12" change="g.47410186del" Assembly="GRCh38">
            <Expression>NC_000002.12:g.47410186del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_007110.2" sequenceAccession="NG_007110" sequenceVersion="2" change="g.12063del">
            <Expression>NG_007110.2:g.12063del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_000251.3" sequenceAccession="NM_000251" sequenceVersion="3" change="c.459del" MANESelect="true">
            <Expression>NM_000251.3:c.459del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_000242.1" sequenceAccession="NP_000242" sequenceVersion="1" change="p.Ala154fs">
            <Expression>NP_000242.1:p.Ala154fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001258281.1" sequenceAccession="NM_001258281" sequenceVersion="1" change="c.261del">
            <Expression>NM_001258281.1:c.261del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001245210.1" sequenceAccession="NP_001245210" sequenceVersion="1" change="p.Ala88fs">
            <Expression>NP_001245210.1:p.Ala88fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="LRG_218" sequenceAccession="LRG_218">
            <Expression>LRG_218:g.12063del</Expression>
          </NucleotideExpression>
        </HGVS>
      </HGVSlist>
      <XRefList>
        <XRef Type="rs" ID="2104023773" DB="dbSNP" />
      </XRefList>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_000251.3(MSH2):c.459del (p.Ala154fs) AND Endometrial carcinoma" Accession="RCV001354085" Version="2">
        <ClassifiedConditionList TraitSetID="1474">
          <ClassifiedCondition DB="MedGen" ID="C0476089">Endometrial carcinoma</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>no assertion criteria provided</ReviewStatus>
            <Description SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_000251.3(MSH2):c.459del (p.Ala154fs) AND Lynch syndrome" Accession="RCV001358629" Version="2">
        <ClassifiedConditionList TraitSetID="8777">
          <ClassifiedCondition DB="MedGen" ID="C4552100">Lynch syndrome</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>no assertion criteria provided</ReviewStatus>
            <Description SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_000251.3(MSH2):c.459del (p.Ala154fs) AND Carcinoma of colon" Accession="RCV001357715" Version="2">
        <ClassifiedConditionList TraitSetID="1735">
          <ClassifiedCondition DB="MedGen" ID="C0699790">Carcinoma of colon</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>no assertion criteria provided</ReviewStatus>
            <Description SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_000251.3(MSH2):c.459del (p.Ala154fs) AND Lynch syndrome 1" Accession="RCV003449989" Version="1">
        <ClassifiedConditionList TraitSetID="451">
          <ClassifiedCondition DB="MedGen" ID="C2936783">Lynch syndrome 1</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2023-07-27" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2023-07-27" NumberOfSubmissions="4" NumberOfSubmitters="2" DateCreated="2021-04-13" MostRecentSubmission="2023-12-24">
        <ReviewStatus>criteria provided, single submitter</ReviewStatus>
        <Description>Pathogenic</Description>
        <ConditionList>
          <TraitSet ID="8777" Type="Disease" ContributesToAggregateClassification="false">
            <Trait ID="14688" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Lynch syndrome</ElementValue>
                <XRef ID="2622" DB="GeneTests" />
                <XRef ID="Hereditary+Non-Polyposis+Colorectal+Cancer+%28HNPCC%29/3371" DB="Genetic Alliance" />
                <XRef ID="MONDO:0005835" DB="MONDO" />
              </Name>
              <AttributeSet>
                <Attribute Type="public definition">Lynch syndrome is characterized by an increased risk for colorectal cancer (CRC) and cancers of the endometrium, ovary, stomach, small bowel, urinary tract, biliary tract, brain (usually glioblastoma), skin (sebaceous adenomas, sebaceous carcinomas, and keratoacanthomas), pancreas, and prostate. Cancer risks and age of onset vary depending on the associated gene. Several other cancer types have been reported to occur in individuals with Lynch syndrome (e.g., breast, sarcomas, adrenocortical carcinoma). However, the data are not sufficient to demonstrate that the risk of developing these cancers is increased in individuals with Lynch syndrome.</Attribute>
                <XRef ID="NBK1211" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="disease mechanism" integerValue="273">loss of function</Attribute>
                <XRef ID="GTR000530202" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000530120" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000551463" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000520867" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000316595" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000552440" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000591173" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000322202" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000520394" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000528915" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000551459" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000520868" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000558908" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000520392" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000515821" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000321105" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000515534" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000522224" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000512828" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000520080" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000569958" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000512403" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000518999" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000552245" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000520871" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000552184" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000558503" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000515774" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000528930" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000528534" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000519150" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000527984" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000570011" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000591263" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000520872" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000520030" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000561860" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000551464" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000562151" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000522225" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000332519" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000528914" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000551450" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000325623" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000530028" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000528529" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000522559" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000520870" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000527983" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000520869" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000569916" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000519254" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000568362" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000527981" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000522278" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000529017" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000604264" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000518997" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000568365" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000520865" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000552183" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000551461" DB="Genetic Testing Registry (GTR)" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="9905" />
                <XRef ID="9905" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301390</ID>
                <ID Source="BookShelf">NBK1211</ID>
              </Citation>
              <Citation Type="general" Abbrev="EGAPP, 2009">
                <ID Source="pmc">2743612</ID>
              </Citation>
              <Citation Type="general" Abbrev="ASCRS, 2001">
                <ID Source="PubMed">11598466</ID>
              </Citation>
              <Citation Type="general" Abbrev="NSGC, 2004">
                <ID Source="PubMed">15604628</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2013">
                <ID Source="PubMed">23788249</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="AMA/NCHPEG, 2012">
                <URL>http://www.nchpeg.org/documents/crc/11-0456%20Fact%20sheets%20(MSI%20and%20IHC%20testing).pdf</URL>
              </Citation>
              <Citation Type="practice guideline" Abbrev="SGO, 2014">
                <URL>https://www.sgo.org/clinical-practice/guidelines/screening-for-lynch-syndrome-in-endometrial-cancer</URL>
                <CitationText>Society of Gynecologic Oncology (SGO) Clinical Practice Statement: Screening for Lynch Syndrome in Endometrial Cancer</CitationText>
              </Citation>
              <Citation Type="general" Abbrev="MSTF, 2014">
                <ID Source="PubMed">25070057</ID>
              </Citation>
              <Citation Type="general" Abbrev="ASCO, 2014">
                <ID Source="PubMed">24493721</ID>
              </Citation>
              <Citation Type="general" Abbrev="CAPS, 2013">
                <ID Source="pmc">3585492</ID>
              </Citation>
              <Citation Type="general" Abbrev="ASCO/ESMO, 2015">
                <ID Source="PubMed">25452455</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2014">
                <ID Source="PubMed">24310308</ID>
              </Citation>
              <Citation Type="general" Abbrev="Mork et al., 2015">
                <ID Source="PubMed">25711197</ID>
              </Citation>
              <Citation Type="general" Abbrev="Dutch SCG, 2013">
                <ID Source="PubMed">23535968</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACG, 2015">
                <ID Source="PubMed">25645574</ID>
              </Citation>
              <Citation Type="general" Abbrev="Mallorca group, 2013">
                <ID Source="PubMed">23408351</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2015">
                <ID Source="PubMed">25356965</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2016">
                <ID Source="PubMed">27854360</ID>
                <ID Source="DOI">10.1038/gim.2016.190</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NCCN, 2024">
                <URL>https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf</URL>
                <CitationText>NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Colon Cancer, 2024</CitationText>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Genetics of Colorectal Cancer">
                <ID Source="PubMed">26389505</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Breast and Gynecologic Cancers">
                <ID Source="PubMed">26389210</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Cancer Genetics Counseling">
                <ID Source="PubMed">26389258</ID>
              </Citation>
              <Citation Type="general" Abbrev="ASCO, 2015">
                <ID Source="PubMed">26324357</ID>
              </Citation>
              <Citation Type="general" Abbrev="CAPS, 2020">
                <ID Source="PubMed">31672839</ID>
                <ID Source="pmc">7295005</ID>
              </Citation>
              <Citation Type="general" Abbrev="EHTG/ESCP, 2021">
                <ID Source="PubMed">34043773</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="Goldberg et al, 2019">
                <ID Source="PubMed">31302137</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2012">
                <URL>https://www.acmg.net/PDFLibrary/Colon-Cancer.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics Family History ACT Sheet, Colon Cancer (Asymptomatic), 2012</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NICE, 2021">
                <URL>https://www.nice.org.uk/guidance/ng151</URL>
                <CitationText>UK NICE Guideline NG151, Colorectal cancer, 2021</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NICE, 2020">
                <URL>https://www.nice.org.uk/guidance/dg42</URL>
                <CitationText>UK NICE Diagnostics Guidance DG42, Testing strategies for Lynch syndrome in people with endometrial cancer, 2020</CitationText>
              </Citation>
              <XRef ID="144" DB="Orphanet" />
              <XRef ID="C4552100" DB="MedGen" />
              <XRef ID="MONDO:0005835" DB="MONDO" />
            </Trait>
          </TraitSet>
          <TraitSet ID="1735" Type="Disease" ContributesToAggregateClassification="false">
            <Trait ID="10229" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Colonic carcinoma</ElementValue>
                <XRef ID="MONDO:0002032" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Colon carcinoma</ElementValue>
                <XRef ID="MONDO:0002032" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Preferred">Carcinoma of colon</ElementValue>
                <XRef ID="269533000" DB="SNOMED CT" />
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">CRC</ElementValue>
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">Lynch syndrome is characterized by an increased risk for colorectal cancer (CRC) and cancers of the endometrium, ovary, stomach, small bowel, urinary tract, biliary tract, brain (usually glioblastoma), skin (sebaceous adenomas, sebaceous carcinomas, and keratoacanthomas), pancreas, and prostate. Cancer risks and age of onset vary depending on the associated gene. Several other cancer types have been reported to occur in individuals with Lynch syndrome (e.g., breast, sarcomas, adrenocortical carcinoma). However, the data are not sufficient to demonstrate that the risk of developing these cancers is increased in individuals with Lynch syndrome.</Attribute>
                <XRef ID="NBK1211" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">Hereditary cancer syndrome</Attribute>
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301390</ID>
                <ID Source="BookShelf">NBK1211</ID>
              </Citation>
              <Citation Type="general" Abbrev="EGAPP, 2009">
                <ID Source="pmc">2743612</ID>
              </Citation>
              <Citation Type="general" Abbrev="EGAPP, 2009">
                <ID Source="pmc">2743610</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="AMA/NCHPEG, 2012">
                <URL>http://www.nchpeg.org/documents/crc/11-0456%20Fact%20sheets%20(MSI%20and%20IHC%20testing).pdf</URL>
              </Citation>
              <Citation Type="general" Abbrev="NACB, 2008">
                <ID Source="PubMed">19042984</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="AHRQ, 2013">
                <URL>https://www.cms.gov/Medicare/Coverage/DeterminationProcess/downloads/id90TA.pdf</URL>
                <CitationText>Technology Assessment on Genetic Testing or Molecular Pathology Testing of Cancers with Unknown Primary Site to Determine Origin (ARCHIVED)</CitationText>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="Imperiale et al., 2014">
                <ID Source="PubMed">25006736</ID>
              </Citation>
              <Citation Type="general" Abbrev="ASCO, 2006">
                <ID Source="PubMed">17060676</ID>
              </Citation>
              <Citation Type="Translational/Evidence-based" Abbrev="NCCN, 2011">
                <ID Source="PubMed">22138009</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACP MPDG, 2014">
                <ID Source="PubMed">24996433</ID>
              </Citation>
              <Citation Type="general" Abbrev="SEAP/SEOM, 2012">
                <ID Source="PubMed">22855150</ID>
              </Citation>
              <Citation Type="general" Abbrev="ESMO, 2012">
                <ID Source="PubMed">23012255</ID>
              </Citation>
              <Citation Type="general" Abbrev="SEAP/SEOM, 2015">
                <ID Source="PubMed">25373533</ID>
              </Citation>
              <Citation Type="general" Abbrev="EGTM, 2014">
                <ID Source="PubMed">23852704</ID>
              </Citation>
              <Citation Type="general" Abbrev="EGAPP, 2013">
                <ID Source="PubMed">23429431</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NCCN, 2024">
                <URL>https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf</URL>
                <CitationText>NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Colon Cancer, 2024</CitationText>
              </Citation>
              <Citation Type="general" Abbrev="EHTG/ESCP, 2021">
                <ID Source="PubMed">34043773</ID>
              </Citation>
              <Citation Type="general" Abbrev="SEAP/SEOM, 2020">
                <ID Source="PubMed">32418154</ID>
                <ID Source="pmc">7505870</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2012">
                <URL>https://www.acmg.net/PDFLibrary/Colon-Cancer.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics Family History ACT Sheet, Colon Cancer (Asymptomatic), 2012</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NICE, 2021">
                <URL>https://www.nice.org.uk/guidance/ng151</URL>
                <CitationText>UK NICE Guideline NG151, Colorectal cancer, 2021</CitationText>
              </Citation>
              <XRef ID="C0699790" DB="MedGen" />
              <XRef ID="MONDO:0002032" DB="MONDO" />
            </Trait>
          </TraitSet>
          <TraitSet ID="1474" Type="Disease" ContributesToAggregateClassification="false">
            <Trait ID="1151" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Endometrial carcinoma</ElementValue>
                <XRef ID="Endometrial+cancer/8312" DB="Genetic Alliance" />
                <XRef ID="HP:0012114" DB="Human Phenotype Ontology" />
                <XRef ID="MONDO:0002447" DB="MONDO" />
                <XRef ID="254878006" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Endometrial carcinoma, somatic</ElementValue>
              </Name>
              <AttributeSet>
                <Attribute Type="keyword">Hereditary cancer syndrome</Attribute>
              </AttributeSet>
              <Citation Type="practice guideline" Abbrev="AHRQ, 2013">
                <URL>https://www.cms.gov/Medicare/Coverage/DeterminationProcess/downloads/id90TA.pdf</URL>
                <CitationText>Technology Assessment on Genetic Testing or Molecular Pathology Testing of Cancers with Unknown Primary Site to Determine Origin (ARCHIVED)</CitationText>
              </Citation>
              <Citation Type="general" Abbrev="SGO, 2014">
                <ID Source="PubMed">24905773</ID>
              </Citation>
              <Citation Type="general" Abbrev="ASCO, 2014">
                <ID Source="PubMed">24493721</ID>
              </Citation>
              <Citation Type="general" Abbrev="SGO, 2021">
                <ID Source="PubMed">33516529</ID>
              </Citation>
              <Citation Type="general" Abbrev="SGO, 2021">
                <ID Source="PubMed">33451724</ID>
              </Citation>
              <Citation Type="general" Abbrev="SGO, 2014">
                <ID Source="PubMed">24929052</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NICE, 2020">
                <URL>https://www.nice.org.uk/guidance/dg42</URL>
                <CitationText>UK NICE Diagnostics Guidance DG42, Testing strategies for Lynch syndrome in people with endometrial cancer, 2020</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NCCN, 2024">
                <URL>https://www.nccn.org/professionals/physician_gls/pdf/uterine.pdf</URL>
                <CitationText>NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), Uterine Neoplasms, 2024</CitationText>
              </Citation>
              <XRef ID="C0476089" DB="MedGen" />
              <XRef ID="MONDO:0002447" DB="MONDO" />
              <XRef Type="MIM" ID="608089" DB="OMIM" />
              <XRef Type="primary" ID="HP:0012114" DB="Human Phenotype Ontology" />
            </Trait>
          </TraitSet>
          <TraitSet ID="451" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="2582" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Lynch syndrome 1</ElementValue>
                <XRef ID="MONDO:0007356" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">MSH2-Related Lynch Syndrome</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Colorectal cancer, hereditary, nonpolyposis, type 1</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">MSH2-Related Hereditary Non-Polyposis Colon Cancer</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Lynch syndrome I</ElementValue>
                <Citation Type="general" Abbrev="Vasen et al., 2007">
                  <ID Source="pmc">2740877</ID>
                </Citation>
                <XRef ID="Colorectal+Cancer%2C+Hereditary+Nonpolyposis%2C+Type+1/1748" DB="Genetic Alliance" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">COLON CANCER, FAMILIAL NONPOLYPOSIS, TYPE 1</ElementValue>
                <XRef Type="MIM" ID="120435" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Hereditary non-polyposis colorectal cancer, type 1</ElementValue>
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">FCC1</ElementValue>
                <XRef Type="MIM" ID="120435" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">HNPCC1</ElementValue>
                <XRef Type="MIM" ID="120435" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="keyword">Hereditary cancer syndrome</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">Neoplasm</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="15052" />
                <XRef ID="15052" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="disease mechanism" integerValue="273">loss of function</Attribute>
                <XRef ID="GTR000512645" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000501399" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000510683" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000507864" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000595970" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000518997" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000514729" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000569406" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000501401" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000518999" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000558503" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000530120" DB="Genetic Testing Registry (GTR)" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">Lynch syndrome is characterized by an increased risk for colorectal cancer (CRC) and cancers of the endometrium, ovary, stomach, small bowel, urinary tract, biliary tract, brain (usually glioblastoma), skin (sebaceous adenomas, sebaceous carcinomas, and keratoacanthomas), pancreas, and prostate. Cancer risks and age of onset vary depending on the associated gene. Several other cancer types have been reported to occur in individuals with Lynch syndrome (e.g., breast, sarcomas, adrenocortical carcinoma). However, the data are not sufficient to demonstrate that the risk of developing these cancers is increased in individuals with Lynch syndrome.</Attribute>
                <XRef ID="NBK1211" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301390</ID>
                <ID Source="BookShelf">NBK1211</ID>
              </Citation>
              <Citation Type="general" Abbrev="EGAPP, 2009">
                <ID Source="pmc">2743612</ID>
              </Citation>
              <Citation Type="general" Abbrev="ASCO, 2010">
                <ID Source="PubMed">20065170</ID>
              </Citation>
              <Citation Type="general" Abbrev="Vasen et al., 2007">
                <ID Source="pmc">2740877</ID>
              </Citation>
              <Citation Type="general" Abbrev="ASCRS, 2001">
                <ID Source="PubMed">11598466</ID>
              </Citation>
              <Citation Type="Translational/Evidence-based" Abbrev="EuroGenetest, 2010">
                <ID Source="pmc">2987434</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2013">
                <ID Source="PubMed">23788249</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="AMA/NCHPEG, 2012">
                <URL>http://www.nchpeg.org/documents/crc/11-0456%20Fact%20sheets%20(MSI%20and%20IHC%20testing).pdf</URL>
              </Citation>
              <Citation Type="practice guideline" Abbrev="SGO, 2014">
                <URL>https://www.sgo.org/clinical-practice/guidelines/screening-for-lynch-syndrome-in-endometrial-cancer</URL>
                <CitationText>Society of Gynecologic Oncology (SGO) Clinical Practice Statement: Screening for Lynch Syndrome in Endometrial Cancer</CitationText>
              </Citation>
              <Citation Type="general" Abbrev="MSTF, 2014">
                <ID Source="PubMed">25070057</ID>
              </Citation>
              <Citation Type="general" Abbrev="ASCO, 2014">
                <ID Source="PubMed">24493721</ID>
              </Citation>
              <Citation Type="general" Abbrev="CAPS, 2013">
                <ID Source="pmc">3585492</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG/NSGC, 2015">
                <ID Source="PubMed">25394175</ID>
              </Citation>
              <Citation Type="general" Abbrev="ASCO/ESMO, 2015">
                <ID Source="PubMed">25452455</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2014">
                <ID Source="PubMed">24310308</ID>
              </Citation>
              <Citation Type="general" Abbrev="Mork et al., 2015">
                <ID Source="PubMed">25711197</ID>
              </Citation>
              <Citation Type="general" Abbrev="Dutch SCG, 2013">
                <ID Source="PubMed">23535968</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACG, 2015">
                <ID Source="PubMed">25645574</ID>
              </Citation>
              <Citation Type="general" Abbrev="Mallorca group, 2013">
                <ID Source="PubMed">23408351</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2015">
                <ID Source="PubMed">25356965</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2016">
                <ID Source="PubMed">27854360</ID>
                <ID Source="DOI">10.1038/gim.2016.190</ID>
              </Citation>
              <Citation Type="general" Abbrev="NSGC/CCA-ICC, 2012">
                <ID Source="PubMed">22167527</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NCCN, 2024">
                <URL>https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf</URL>
                <CitationText>NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Colon Cancer, 2024</CitationText>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Genetics of Colorectal Cancer">
                <ID Source="PubMed">26389505</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Breast and Gynecologic Cancers">
                <ID Source="PubMed">26389210</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Cancer Genetics Counseling">
                <ID Source="PubMed">26389258</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG SF v3.0, 2021">
                <ID Source="PubMed">34012068</ID>
                <ID Source="DOI">10.1038/s41436-021-01172-3</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG SF v3.1, 2022">
                <ID Source="PubMed">35802134</ID>
                <ID Source="DOI">10.1016/j.gim.2022.04.006</ID>
              </Citation>
              <Citation Type="general" Abbrev="ASCO, 2015">
                <ID Source="PubMed">26324357</ID>
              </Citation>
              <Citation Type="general" Abbrev="CAPS, 2020">
                <ID Source="PubMed">31672839</ID>
                <ID Source="pmc">7295005</ID>
              </Citation>
              <Citation Type="general" Abbrev="EHTG/ESCP, 2021">
                <ID Source="PubMed">34043773</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2012">
                <URL>https://www.acmg.net/PDFLibrary/Colon-Cancer.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics Family History ACT Sheet, Colon Cancer (Asymptomatic), 2012</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2019">
                <URL>https://www.acmg.net/PDFLibrary/Lynch-Syndrome.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Genomic Testing (Secondary Findings) ACT Sheet, MLH1, MSH2, MSH6, PMS2, EPCAM Pathogenic Variants, Lynch Syndrome (Hereditary Non-polyposis Colon Cancer [HNPCC]), 2019</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NICE, 2021">
                <URL>https://www.nice.org.uk/guidance/ng151</URL>
                <CitationText>UK NICE Guideline NG151, Colorectal cancer, 2021</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NICE, 2020">
                <URL>https://www.nice.org.uk/guidance/dg42</URL>
                <CitationText>UK NICE Diagnostics Guidance DG42, Testing strategies for Lynch syndrome in people with endometrial cancer, 2020</CitationText>
              </Citation>
              <XRef ID="144" DB="Orphanet" />
              <XRef ID="C2936783" DB="MedGen" />
              <XRef ID="MONDO:0007356" DB="MONDO" />
              <XRef Type="MIM" ID="120435" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="3049236" SubmissionDate="2021-03-31" DateLastUpdated="2021-04-13" DateCreated="2021-04-13">
        <ClinVarSubmissionID localKey="chr2:47637322-47637324:1e8b763a44076fb61edb1f0115e0844f-ENDOMETRIAL" localKeyIsSubmitted="1" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV001548613" DateUpdated="2021-04-13" DateCreated="2021-04-13" Type="SCV" Version="1" SubmitterName="Department of Pathology and Laboratory Medicine, Sinai Health System" OrgID="506152" OrganizationCategory="laboratory" OrgAbbreviation="PLM-SHS" />
        <AdditionalSubmitters>
          <SubmitterDescription OrgID="506759" SubmitterName="Franklin by Genoox" Type="secondary" OrganizationCategory="other" />
        </AdditionalSubmitters>
        <RecordStatus>current</RecordStatus>
        <Classification>
          <ReviewStatus>no assertion criteria provided</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Comment>The MSH2 p.Ala154GlnfsX20 variant was not identified in the literature nor was it identified in the following databases: dbSNP, ClinVar, UMD-LSDB, the Exome Aggregation Consortium (August 8th 2016) or the Genome Aggregation Database (Feb 27, 2017). The c.459del variant is predicted to cause a frameshift, which alters the protein's amino acid sequence beginning at codon 154 and leads to a premature stop codon 20 codons downstream. This alteration is then predicted to result in a truncated or absent protein and loss of function. Loss of function variants of the MSH2 gene are an established mechanism of disease in Lynch Syndrome and is the type of variant expected to cause the disorder. In summary, based on the above information this variant meets our laboratoryâ€šÃ„Ã´s criteria to be classified as pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>unknown</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="MSH2" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <Location>
            <SequenceLocation Assembly="GRCh37" Chr="2" alternateAllele="T" referenceAllele="TC" start="47637323" stop="47637324" variantLength="2" />
          </Location>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MONDO" ID="MONDO:0002447" />
          </Trait>
        </TraitSet>
        <StudyName>The Canadian Open Genetics Repository (COGR)</StudyName>
        <SubmissionNameList>
          <SubmissionName>SUB9371647</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="3054421" SubmissionDate="2021-03-31" DateLastUpdated="2021-04-13" DateCreated="2021-04-13">
        <ClinVarSubmissionID localKey="chr2:47637322-47637324:1e8b763a44076fb61edb1f0115e0844f-COLON" localKeyIsSubmitted="1" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV001553266" DateUpdated="2021-04-13" DateCreated="2021-04-13" Type="SCV" Version="1" SubmitterName="Department of Pathology and Laboratory Medicine, Sinai Health System" OrgID="506152" OrganizationCategory="laboratory" OrgAbbreviation="PLM-SHS" />
        <AdditionalSubmitters>
          <SubmitterDescription OrgID="506759" SubmitterName="Franklin by Genoox" Type="secondary" OrganizationCategory="other" />
        </AdditionalSubmitters>
        <RecordStatus>current</RecordStatus>
        <Classification>
          <ReviewStatus>no assertion criteria provided</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Comment>The MSH2 p.Ala154GlnfsX20 variant was not identified in the literature nor was it identified in the following databases: dbSNP, ClinVar, UMD-LSDB, the Exome Aggregation Consortium (August 8th 2016) or the Genome Aggregation Database (Feb 27, 2017). The c.459del variant is predicted to cause a frameshift, which alters the protein's amino acid sequence beginning at codon 154 and leads to a premature stop codon 20 codons downstream. This alteration is then predicted to result in a truncated or absent protein and loss of function. Loss of function variants of the MSH2 gene are an established mechanism of disease in Lynch Syndrome and is the type of variant expected to cause the disorder. In summary, based on the above information this variant meets our laboratoryâ€šÃ„Ã´s criteria to be classified as pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>unknown</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="MSH2" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <Location>
            <SequenceLocation Assembly="GRCh37" Chr="2" alternateAllele="T" referenceAllele="TC" start="47637323" stop="47637324" variantLength="2" />
          </Location>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MONDO" ID="MONDO:0002032" />
          </Trait>
        </TraitSet>
        <StudyName>The Canadian Open Genetics Repository (COGR)</StudyName>
        <SubmissionNameList>
          <SubmissionName>SUB9371647</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="3055690" SubmissionDate="2021-03-31" DateLastUpdated="2021-04-13" DateCreated="2021-04-13">
        <ClinVarSubmissionID localKey="chr2:47637322-47637324:1e8b763a44076fb61edb1f0115e0844f-CERVICAL" localKeyIsSubmitted="1" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV001554420" DateUpdated="2021-04-13" DateCreated="2021-04-13" Type="SCV" Version="1" SubmitterName="Department of Pathology and Laboratory Medicine, Sinai Health System" OrgID="506152" OrganizationCategory="laboratory" OrgAbbreviation="PLM-SHS" />
        <AdditionalSubmitters>
          <SubmitterDescription OrgID="506759" SubmitterName="Franklin by Genoox" Type="secondary" OrganizationCategory="other" />
        </AdditionalSubmitters>
        <RecordStatus>current</RecordStatus>
        <Classification>
          <ReviewStatus>no assertion criteria provided</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Comment>The MSH2 p.Ala154GlnfsX20 variant was not identified in the literature nor was it identified in the following databases: dbSNP, ClinVar, UMD-LSDB, the Exome Aggregation Consortium (August 8th 2016) or the Genome Aggregation Database (Feb 27, 2017). The c.459del variant is predicted to cause a frameshift, which alters the protein's amino acid sequence beginning at codon 154 and leads to a premature stop codon 20 codons downstream. This alteration is then predicted to result in a truncated or absent protein and loss of function. Loss of function variants of the MSH2 gene are an established mechanism of disease in Lynch Syndrome and is the type of variant expected to cause the disorder. In summary, based on the above information this variant meets our laboratoryâ€šÃ„Ã´s criteria to be classified as pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>unknown</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="MSH2" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <Location>
            <SequenceLocation Assembly="GRCh37" Chr="2" alternateAllele="T" referenceAllele="TC" start="47637323" stop="47637324" variantLength="2" />
          </Location>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MONDO" ID="MONDO:0005835" />
          </Trait>
        </TraitSet>
        <StudyName>The Canadian Open Genetics Repository (COGR)</StudyName>
        <SubmissionNameList>
          <SubmissionName>SUB9371647</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="7825603" SubmissionDate="2023-12-21" DateLastUpdated="2023-12-24" DateCreated="2023-12-24">
        <ClinVarSubmissionID localKey="100707310|OMIM:120435" />
        <ClinVarAccession Accession="SCV004187037" DateUpdated="2023-12-24" DateCreated="2023-12-24" Type="SCV" Version="1" SubmitterName="Myriad Genetics, Inc." OrgID="507240" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2023-07-27">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Comment>This variant is considered pathogenic. This variant creates a frameshift predicted to result in premature protein truncation.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Myriad Autosomal Dominant, Autosomal Recessive and X-Linked Classification Criteria (2023)</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/ft/byid/8ufcwsf2/myriad_genetics_classification_criteria_2023.pdf</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>unknown</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="MSH2" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <Location>
            <SequenceLocation Assembly="hg19" Chr="2" alternateAllele="C" referenceAllele="CC" start="47637324" stop="47637325" />
          </Location>
          <OtherNameList>
            <Name Type="SubmitterVariantId">100707310</Name>
          </OtherNameList>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="120435" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB14104645</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="3055690" TraitType="Disease" MappingType="XRef" MappingValue="MONDO:0005835" MappingRef="MONDO">
        <MedGen CUI="C4552100" Name="Lynch syndrome" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="3054421" TraitType="Disease" MappingType="XRef" MappingValue="MONDO:0002032" MappingRef="MONDO">
        <MedGen CUI="C0699790" Name="Carcinoma of colon" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="3049236" TraitType="Disease" MappingType="XRef" MappingValue="MONDO:0002447" MappingRef="MONDO">
        <MedGen CUI="C0476089" Name="Endometrial carcinoma" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="7825603" TraitType="Disease" MappingType="XRef" MappingValue="120435" MappingRef="OMIM">
        <MedGen CUI="C2936783" Name="Lynch syndrome 1" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

